Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05904132 · ClinicalTrials.gov registry record · NA

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

A NA study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT05904132 is a NA study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05904132, a NA study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and complete some questionnaires and computer tasks during each study visit. The project has the following aims and hypotheses: 1.) To determine the impact of closed-loop 40 Hz tACS on the entrainment of natural gamma rhythms in patients with AD-MCI, 2.) To determine the impact of closed-loop 40 Hz tACS on cognitive performance in patients with AD-MCI, and 3.) To assess the relationship between baseline neurodegenerative burden and impact of tACS. \[exploratory\]

Interventions

  • DEVICE tACS device

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Charlestown

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-01-31
Est. Completion 2026-06
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05904132

The ClinicalTrials.gov registry entry for NCT05904132 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which tACS device is the first listed.

NCT05904132 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05904132 about?

NCT05904132 is a clinical study titled "Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease". The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and co...

What is the current status of trial NCT05904132?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-01-31. Estimated completion is 2026-06.

What conditions does trial NCT05904132 study?

This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment.

What interventions are being tested in trial NCT05904132?

The interventions under investigation include: tACS device (DEVICE).

Who is sponsoring clinical trial NCT05904132?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05904132 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.